The PURPOSE 1 trial1 demonstrated that after 52 weeks, no cisgender women acquired HIV infection after receiving subcutaneous twice-yearly lenacapavir. HIV incidence with lenacapavir was significantly lower than HIV incidence with daily oral emtricitabine/tenofovir alafenamide (F/TAF) or daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF). It is the first pre-exposure prophylaxis regimen with 100% efficacy in young women.
Twice-yearly lenacapavir: A milestone for HIV prevention in young African women / Nozza, S.; Castagna, A.. - In: MED. - ISSN 2666-6340. - 5:10(2024), pp. 1200-1202. [10.1016/j.medj.2024.08.008]
Twice-yearly lenacapavir: A milestone for HIV prevention in young African women
Nozza S.;Castagna A.
2024-01-01
Abstract
The PURPOSE 1 trial1 demonstrated that after 52 weeks, no cisgender women acquired HIV infection after receiving subcutaneous twice-yearly lenacapavir. HIV incidence with lenacapavir was significantly lower than HIV incidence with daily oral emtricitabine/tenofovir alafenamide (F/TAF) or daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF). It is the first pre-exposure prophylaxis regimen with 100% efficacy in young women.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
